RegeneRx explores strategic options

2 February 2012

US biotech firm RegeneRx Biopharmaceuticals. (OTC Bulletin Board: RGRX) revealed yesterday that it has hired investment bankers, Ameritech Advisors and Aurora Capital to help the company evaluate and explore potential strategic opportunities.

Additionally, RegeneRx is continuing to move forward in early-stage discussions with potential strategic partners related to its ophthalmic drug candidate, RGN-259 for the treatment of dry eye, which it had previously announced. During the past few weeks, a number of additional companies have expressed interest in exploring a partnering transaction involving RGN-259 or a broader strategic transaction, and the company is exploring these opportunities as well.

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair and regeneration. The company currently has three drug candidates in clinical development and has an extensive worldwide patent portfolio covering its products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK